At the upcoming Annual Meeting of the European Society of Retina Specialists (EURETINA) in Barcelona, Spain, from September 19-22, 2024, Bayer will present new findings from the pivotal PULSAR and PHOTON trials on Eylea™ (aflibercept 8 mg). These studies focus on the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).
A notable indirect comparison between aflibercept 8 mg and faricimab will assess the timing and extent of disease activity using consistent criteria across phase 3 trials in nAMD. Additionally, fluid control and intraocular pressure outcomes with Eylea 8 mg are analyzed through week 96 of the PULSAR trial, reinforcing the drug’s durable efficacy and safety.
Professor Anat Loewenstein from Tel Aviv Medical Center emphasized the importance of sustained treatment approaches, highlighting the clinical trial results as a pivotal shift in retinal care.
Key abstracts to be presented include:
- An indirect comparison of aflibercept 8 mg and faricimab on disease activity in nAMD
- Post-hoc analyses from the PULSAR trial examining fluid control and intraocular pressure outcomes
- A pooled safety analysis across multiple trials confirming similar safety profiles between aflibercept 8 mg and 2 mg doses
Additional analyses will explore the impact of treatment schedules on patient outcomes and adherence in nAMD, as well as subgroup outcomes from the PHOTON trial for DME patients.
Eylea™ 8 mg, co-developed by Bayer and Regeneron, is already approved for nAMD and DME in the EU, Japan, and other markets.
